Summary

GSK will discontinue camlipixant, the chronic cough treatment it gained through its acquisition of Bellus Health. Two pivotal trials produced conflicting results. One dose worked in one study and failed in the other. Both studies also missed key secondary goals. As a result, camlipixant becomes the third drug in its class to fail in late-stage testing. Consequently, GSK now closes a programme it acquired for roughly $2 billion.

Access Impact

A failed Phase 3 programme rarely reaches a market access review. However, the pattern behind this failure carries lessons for future dossiers in the same drug class. Inconsistent results across trials and doses are precisely the kind of evidence gap that health technology assessment bodies scrutinize before granting reimbursement. Specifically, when a treatment effect appears in one study but disappears in another, reviewers cannot rule out chance, population differences, or dosing error as the cause. This is not a minor technical issue. It is the difference between a defensible value story and a fragile one. Moreover, the failure shows that even well-funded, well-designed programmes can produce evidence too weak to support a future access claim. In addition, it underlines why access risk should be assessed well before a late-stage readout, not after.

Evidence Quality and Robustness

The core problem here is evidence, not marketing or pricing strategy. In the first pivotal study, the 50 milligram twice-daily dose reduced cough frequency compared to placebo. In the second study, the same dose failed. A lower, 25 milligram dose failed in both trials. Both studies also missed key secondary goals. Consequently, no single dose produced a consistent, repeatable signal. For any HTA body, a treatment effect that appears and disappears across trials is difficult to trust, regardless of how promising the mechanism looked in earlier testing. By contrast, a therapy that shows the same effect size across doses and studies gives reviewers a much easier case to accept. Therefore, replication across trials, not a single strong result, is what evidence review ultimately rewards.

Comparator Appropriateness

Camlipixant’s failure changes the competitive picture for chronic cough. Trevi Therapeutics, a smaller rival, is developing Haduvio, an opioid repurposed from pain relief for use in chronic cough. Analysts have already described camlipixant’s exit as an “open field opportunity” for Trevi. Notably, any comparator assessment in this indication now has one fewer credible option to weigh Haduvio against. This shift shows how quickly a competitive-landscape assumption can change, and why comparator selection needs continuous, not one-time, scrutiny. As a result, any earlier analysis built around camlipixant as the leading comparator now needs revisiting. Even so, patients and prescribers are left waiting longer for a validated alternative.

Residual Uncertainty and Equity

Patients with refractory chronic cough still have very few treatment options. Therefore, the practical consequence of this failure falls on them as much as on GSK’s balance sheet. Furthermore, the setback raises a broader question for the field: how many other P2X3 antagonists, camlipixant’s drug class, will fail before a viable comparator profile can be established for regulators and payers? Uncertainty of this kind does not resolve on its own. It compounds with every failed programme. This is exactly the type of residual risk a portfolio-level review should surface before capital is committed, not after. Instead of being treated as an isolated setback, this failure should inform how the next asset in the same class is diligenced and priced.

Risk Signal

A $2 billion acquisition did not buy a working drug. For decision-makers, that is the headline, not the footnote. Jefferies analysts noted that the failure is “disappointing” but not “a material setback” to GSK’s broader equity story, since the company’s investment case now centers on oncology. Even so, the episode is a reminder that deal size and evidence strength are not the same thing. Internal forecasts, built on early or mid-stage data, consistently overestimate the odds of late-stage and access success. Without an external, standardized benchmark, this gap between forecast and outcome tends to repeat itself across deals and drug classes. Before the next acquisition closes, what independent, defensible benchmark will confirm the evidence is strong enough to survive scrutiny?

#MarketAccess #HTA #MARArating #GSK

Explore a related independent assessment in Respiratory: https://mararating.com/report/jascayd-for-treating-idiopathic-pulmonary-fibrosis-or-progressive-pulmonary-fibrosis-as-of-june-2026/

Explore a related independent assessment in Respiratory: https://mararating.com/report/enflonsia-clesrovimab-cfor-for-prevention-of-rsv-lower-respiratory-tract-disease-in-neonates-and-infants-as-of-february-2026/